These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 3706317)

  • 1. Controversies in antimicrobial therapy: formulary decisions on third-generation cephalosporins.
    Barriere SL
    Am J Hosp Pharm; 1986 Mar; 43(3):625-9. PubMed ID: 3706317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulary evaluation of third-generation cephalosporins using decision analysis.
    Cano SB; Fujita NK
    Am J Hosp Pharm; 1988 Mar; 45(3):566-9. PubMed ID: 3285673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Institution-specific versus published in vitro antimicrobial susceptibility data in making formulary decisions.
    Franson TR; DaMert GJ; Sheth NK; Wisniewski T; Cooper JE; Johnson R; Babcock JB; Hoffmann RG; Malangoni MA
    Am J Hosp Pharm; 1987 Jan; 44(1):95-101. PubMed ID: 3826095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of decision analysis to drug selection for formulary addition.
    Kresel JJ; Hutchings HC; MacKay DN; Weinstein MC; Read JL; Taylor-Halvorsen K; Ashley H
    Hosp Formul; 1987 Jul; 22(7):658-63, 673, 676. PubMed ID: 10282682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Third-generation cephalosporins: a critical evaluation.
    Barriere SL; Flaherty JF
    Clin Pharm; 1984; 3(4):351-73. PubMed ID: 6432420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial formulary management: meeting the challenge in the community hospital.
    Rush DR
    Pharmacotherapy; 1991; 11(1 ( Pt 2)):19S-26S. PubMed ID: 2011569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Review of oral cephalosporins. Basis for a rational choice].
    Forti IN
    Medicina (B Aires); 1994; 54(5 Pt 1):439-58. PubMed ID: 7658980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methods of controlling cephalosporin use in Canadian hospitals.
    Godin JP; Sketris IS; Merrett RA; Marrie TJ
    Can J Hosp Pharm; 1988 Apr; 41(2):73-4, 83-4, 96. PubMed ID: 10287052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobials and therapeutic decision making: an historical perspective.
    Quintiliani R; Nightingale CH
    Pharmacotherapy; 1991; 11(1 ( Pt 2)):6S-13S. PubMed ID: 2011573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Financial impact of formulary revision of second-generation cephalosporins.
    Andrews JD; Hafting S
    Can J Hosp Pharm; 1988 Jun; 41(3):125-7. PubMed ID: 10288499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter model for examining in vitro susceptibilities of bacteria to antibiotics.
    Day D; Mangi R; Jenkins S; Ivey MF
    Hosp Formul; 1989 Sep; 24(9):513-6, 519-20, 523. PubMed ID: 10294666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cephalosporin-use restrictions in teaching hospitals.
    McCloskey WW; Johnson PN; Jeffrey LP
    Am J Hosp Pharm; 1984 Nov; 41(11):2359-62. PubMed ID: 6507437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial stewardship.
    Rybak MJ
    Pharmacotherapy; 2007 Oct; 27(10 Pt 2):131S-135S. PubMed ID: 17896906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulary decision making: identifying factors that influence P&T committee drug evaluations.
    Segal R; Pathak DS
    Hosp Formul; 1988 Feb; 23(2):174-8. PubMed ID: 10286022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computer-assisted antimicrobial-use monitoring.
    Inaraja MT; Paloma JM; Giráldez J; Idoate AJ; Hualde S
    Am J Hosp Pharm; 1986 Mar; 43(3):664-70. PubMed ID: 3754692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hospital-based strategies for combating resistance.
    Owens RC; Rice L
    Clin Infect Dis; 2006 Apr; 42 Suppl 4():S173-81. PubMed ID: 16544268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug formulary review process for sargramostim and filgrastim: focus on analysis of adverse drug reactions.
    Kellihan MJ
    Clin Ther; 1993; 15(5):927-37. PubMed ID: 7505717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cephalosporin selection: view from a beleaguered P & T committee member.
    Talley JH
    Hosp Formul; 1986 Jan; 21(1):76-8, 83-4. PubMed ID: 10275082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug costs and bacterial susceptibility after implementing a single-fluoroquinolone use policy at a university hospital.
    Rapp RP; Evans ME; Martin C; Ofotokum I; Empey KL; Armitstead JA
    Curr Med Res Opin; 2004 Apr; 20(4):469-76. PubMed ID: 15119984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulary decisions concerning cephalosporins.
    Fuentes RJ
    Am J Hosp Pharm; 1979 Mar; 36(3):296, 300. PubMed ID: 420220
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.